Emergent BioSolutions Inc.
EBS
$9.12
-$0.115-1.25%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.68% | -26.03% | -29.61% | 8.61% | -24.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.68% | -26.03% | -29.61% | 8.61% | -24.62% |
| Cost of Revenue | -74.95% | -35.59% | -45.81% | -27.23% | 49.28% |
| Gross Profit | 192.67% | -15.20% | -19.33% | 77.71% | -153.08% |
| SG&A Expenses | -43.08% | -37.85% | -32.10% | -4.77% | -15.33% |
| Depreciation & Amortization | -0.61% | 0.62% | 0.62% | 0.00% | 1.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.07% | -34.08% | -37.58% | -19.08% | 28.55% |
| Operating Income | 100.31% | 26.63% | 89.81% | 2,100.00% | -1,094.38% |
| Income Before Tax | 93.77% | 666.12% | 49.36% | 153.55% | -7.83% |
| Income Tax Expenses | -136.09% | 696.77% | 174.00% | 1,204.00% | 18.75% |
| Earnings from Continuing Operations | 95.76% | 655.56% | 36.77% | 143.58% | -8.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 95.76% | 655.56% | 36.77% | 143.58% | -8.30% |
| EBIT | 100.31% | 26.63% | 89.81% | 2,100.00% | -1,094.38% |
| EBITDA | 117.87% | 12.57% | 255.56% | 319.31% | -373.96% |
| EPS Basic | 95.89% | 625.06% | 39.45% | 142.52% | -4.39% |
| Normalized Basic EPS | 90.63% | 673.08% | 60.53% | 412.69% | -1,003.10% |
| EPS Diluted | 95.89% | 600.00% | 39.22% | 140.51% | -4.30% |
| Normalized Diluted EPS | 90.63% | 633.95% | 60.53% | 398.63% | -1,003.10% |
| Average Basic Shares Outstanding | 3.04% | 4.21% | 4.43% | 2.51% | 3.75% |
| Average Diluted Shares Outstanding | 3.04% | 9.77% | 4.43% | 7.34% | 3.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |